Atypical Kawasaki Disease

1. DEFINITION

Atypical Kawasaki Disease (KD) refers to a presentation where patients manifest unusual, severe, or organ-specific clinical signs that are not classically associated with the standard mucocutaneous diagnostic criteria of KD.
These atypical features can dominate the clinical picture, occur concurrently with, or precede classic mucocutaneous criteria, frequently masking the underlying systemic vasculitis and leading to hazardous diagnostic delays.

The fundamental pathology is a systemic necrotizing vasculitis of medium-sized muscular arteries.
In atypical KD, the intense inflammatory burden, endothelial damage, and cytokine storm (driven by TNF-alpha, IL-1, and IL-6) disproportionately target distinct end-organ vascular beds (e.g., myocardium, meninges, biliary tree, renal parenchyma) rather than being confined to the mucocutaneous surfaces and coronary arteries.
Localized microvascular leakage and focal tissue ischemia result in pronounced, organ-specific clinical syndromes.

A. Cardiovascular Manifestations

Kawasaki Disease Shock Syndrome (KDSS): Characterized by profound distributive (vasoplegic) and/or cardiogenic shock requiring fluid resuscitation and inotropic support.
Severe Myocarditis: Leading to clinically significant depression of left ventricular ejection fraction and congestive heart failure.
Pericarditis: With significant pericardial effusions and risk of impending tamponade.
Peripheral gangrene/ischemia of the digits early in the disease course.

B. Gastrointestinal and Hepatic Manifestations

Surgical Abdomen Mimic: Severe colicky abdominal pain, guarding, and rigidity often leading to unnecessary exploratory laparotomy.
Hepatobiliary: Hydrops of the gallbladder (non-calculous distension), acalculous cholecystitis, prominent hepatomegaly, and obstructive jaundice.
Gastrointestinal Tract: Paralytic ileus, hemorrhagic enteritis, and severe diarrhea.

C. Neurological Manifestations

Central: Aseptic meningitis, presenting with extreme, disproportionate irritability, lethargy, nuchal rigidity, and bulging fontanelle.
Peripheral: Transient facial nerve palsy and sensorineural hearing loss.

D. Renal and Genitourinary Manifestations

Acute Kidney Injury (AKI) secondary to tubulointerstitial nephritis or ischemic injury from KDSS.
Sterile pyuria (indicative of urethritis).
Nephrotic-range proteinuria.

E. Respiratory Manifestations

Pulmonary infiltrates (reticulonodular or consolidative) mimicking atypical pneumonia.
Exudative pleural effusions.

F. Musculoskeletal Manifestations

Severe, debilitating arthritis or arthralgia (often oligoarticular, involving large weight-bearing joints like knees and hips), heavily restricting mobility before classic signs appear.

Laboratory Hallmarks: Exaggerated elevation of acute phase reactants (CRP, ESR, Procalcitonin). Leukocytosis with marked left shift.
Organ-Specific Biomarkers: Elevated transaminases/bilirubin, elevated BUN/Creatinine, and elevated cardiac biomarkers (Troponin, NT-proBNP).
CSF Analysis: Essential to rule out bacterial meningitis; typically reveals pleocytosis with mononuclear predominance, normal glucose, and normal protein.
Imaging: Abdominal ultrasound (to identify gallbladder hydrops), Chest X-ray.
Echocardiography (Mandatory): Critical for identifying baseline Coronary Artery Abnormalities (CAA), calculating coronary Z-scores, and assessing left ventricular systolic function and valvular regurgitation.

Core Principle: Do not delay treatment. Atypical presentations carry a significantly higher risk for Coronary Artery Aneurysms (CAA) and mortality due to systemic inflammation and diagnostic delays.
Primary Therapy: Intravenous Immunoglobulin (IVIG) 2 g/kg as a single continuous infusion over 10-12 hours, paired with Moderate/High-dose Aspirin (30-50 mg/kg/day) until afebrile for 48 hours. Follow with anti-platelet dosing (3-5 mg/kg/day).
Adjunctive Therapies: Patients with atypical KD (particularly KDSS and severe organ involvement) have a high incidence of IVIG resistance. Early implementation of primary adjunctive therapy is highly indicated:
- Systemic Corticosteroids: Intravenous Methylprednisolone pulse therapy (30 mg/kg/day for 1-3 days).
- Biological agents: Infliximab (TNF-alpha inhibitor) or Anakinra (IL-1 receptor antagonist).
Intensive Care: Immediate organ-specific supportive care (e.g., milrinone or epinephrine for shock, mechanical ventilation for profound cardiopulmonary failure).

Morbidity and mortality are substantially higher in atypical variants compared to classic KD.
There is a markedly increased incidence of giant coronary aneurysms and long-term ischemic heart disease.
Strict cardiological follow-up with serial echocardiograms is required at 1-2 weeks, 4-6 weeks, and long-term based on the severity of coronary involvement.